QuantHealth

Simulation is the entire offering. The Large Real-World Drug Model is described as a clinical trial foundation model trained on real world data from more than 350 million patients and large volumes of therapeutic datapoints, used to predict individual patient response and aggregate those into a simulated trial result. There is no consulting or data brokerage layer being dressed as AI; the model output is the deliverable.

Structurally low risk on this axis because nothing the model produces touches a patient. Output informs protocol design decisions made by clinical development and operations teams: inclusion and exclusion criteria, comparator arms, endpoints, indication selection. The real exposure is different from clinical AI and worth naming plainly: a simulation that wrongly predicts a subgroup will not respond could exclude that population from a trial, which shapes who the eventual therapy is studied in and labeled for. Human sponsors retain every decision, but the influence on trial design is substantive rather than advisory.

Scale is disclosed specifically while method is not. The company names the model, its training base of more than 350 million patients, and its versioning, and reports headline accuracy figures including 88 percent for Phase 2 and 83.2 percent for Phase 3 predictions. What is missing is how accuracy is defined and validated, whether predictions were made prospectively before readout or fitted retrospectively, and what counts as a correct prediction of a trial outcome. Vendor materials state predictions are made without sponsor data at 85 percent accuracy on primary endpoints, but no peer reviewed methodology paper was located to substantiate the claim.

Volume of reported activity is substantial but the evidence is almost entirely vendor generated. The company reports simulating more than 350 trials across 23 therapeutic areas with up to 90 percent predictive accuracy, having grown from a reported 100 simulations at 85 percent accuracy, and cites a case where simulation identified a likely non responder subgroup for a top ten pharmaceutical company with 31.4 million dollars in claimed savings. None of these figures were independently verified in this review, the pharmaceutical partner is unnamed, and no peer reviewed publication was located. Strategic investment from a major pharmaceutical venture arm and an Accenture backed funding round are meaningful third party signals of credibility, but they are commercial rather than scientific validation. Contrast with Unlearn.AI, whose comparable claims sit in peer reviewed literature and a regulatory qualification.

No specific PHI handling or data governance framework was located. The platform is trained on large real world datasets acquired through data partnerships, which raises provenance and consent questions that are not addressed publicly.

No HIPAA or BAA commitment was located. Customers are trial sponsors rather than provider organizations, so contracting typically runs through sponsor agreements, but the posture is not published.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

No FDA regulated pathway applies and none is claimed, since trial simulation informs sponsor design decisions rather than diagnosing or treating patients. Worth noting by contrast that Unlearn.AI, operating in adjacent territory, pursued and obtained an EMA qualification opinion for its methodology, demonstrating that a regulatory route exists for trial methodology even where device regulation does not apply. No equivalent qualification was located here.

No formal governance framework, subgroup performance analysis, or bias disclosure was located. This gap carries specific weight for this product class: a model trained on historical real world data inherits that data's demographic composition, and using it to predict non responder subgroups could systematically narrow trial populations along the same lines. Nothing was located addressing how the company guards against that.

Not applicable in the usual sense and not claimed. The platform operates on aggregated real world datasets within sponsor development workflows rather than integrating with provider systems. Data partnerships extend the underlying dataset, but no integration surface with clinical or trial operations systems was enumerated.

No hosting, tenancy, or data residency terms were located in the materials reviewed.

No pricing is published. The company quantifies value in customer savings terms, citing 31.4 million dollars delivered to one unnamed pharmaceutical company, which is a return claim rather than a cost disclosure and cannot be independently checked. The engagement model appears to be enterprise partnership with pharmaceutical sponsors rather than licensed software, and terms are not disclosed.

Broad by design and broader than comparable vendors. Deployment spans a reported 23 therapeutic areas including oncology, immunology, cardiometabolic disease, and gastroenterology, and capability covers trial design optimization, indication selection, drug repurposing, asset evaluation, and probability of technical success modeling across development phases. That breadth contrasts sharply with Unlearn.AI, whose coverage is bounded by disease specific twin generators and continuous endpoints. Breadth here reflects a general purpose model rather than per disease qualification, which is a strength commercially and a weakness evidentially.